RPID RAPID MICRO BIOSYSTEMS INC

Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025

Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025

LEXINGTON, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release fourth quarter and full year 2024 financial results prior to the market open on Friday, February 28, 2025.

In conjunction with the release, the Company’s management team will host a webcast conference call at 8:00 a.m. ET on Friday, February 28, 2025. The live audio webcast will be accessible on the Company’s website and can be accessed with this . The webcast will be archived and available for replay after the event.

About Rapid Micro Biosystems

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit  or follow the Company on X (formerly known as Twitter) at  or on .



Investor Contact:
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
  

Media Contact:
  
EN
20/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RAPID MICRO BIOSYSTEMS INC

 PRESS RELEASE

Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results

Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results Reports second quarter 2025 total revenue of $7.3 million, representing 10% growth compared to the second quarter of 2024. Second quarter 2025 recurring revenue increased 15% compared to the second quarter of 2024. Reports second quarter gross margin of 4%, representing a seven-percentage point improvement compared to the second quarter of 2024. Enters into five-year, $45 million term loan facility with $20 million funded at close. Reaffirms full-year 2025 total revenue guidance of at least $32....

 PRESS RELEASE

Rapid Micro Biosystems Enters into Five-Year, $45 Million Term Loan Fa...

Rapid Micro Biosystems Enters into Five-Year, $45 Million Term Loan Facility with Trinity Capital Inc. $20 million drawn down at closing, with access to up to an additional $25 million Strengthens Company’s financial position and reinforces ability to achieve positive cash flow LEXINGTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company” or “Rapid Micro”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare produc...

 PRESS RELEASE

Rapid Micro Biosystems to Announce Second Quarter 2025 Financial Resul...

Rapid Micro Biosystems to Announce Second Quarter 2025 Financial Results on August 12, 2025 LEXINGTON, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2025 financial results prior to the market open on Tuesday, August 12, 2025. In conjunction with the release, the Company’s management team will host a webcast conference call a...

 PRESS RELEASE

Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listin...

Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LEXINGTON, Mass., June 13, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the grants on June 2, 2025, of (i) 160,000 restricted stock units (“RSUs”) of the Company’s Class A common stock (“Common Stock”) and (ii) non-qualified stock options to purchase an aggregate of...

 PRESS RELEASE

Rapid Micro Biosystems Announces Appointment of Dr. Dafni Bika to Boar...

Rapid Micro Biosystems Announces Appointment of Dr. Dafni Bika to Board of Directors LEXINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company” or “Rapid Micro”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to welcome Dr. Dafni Bika to the Company’s Board of Directors (the “Board”). “We are extremely pleased to welcome Dr. Bika to our Board of Directors,” said Robert Spignesi, President an...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch